mRNA-1010

Phase 3Completed

1 views this week 0 watching

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Seasonal Influenza

Conditions

Seasonal Influenza

Trial Timeline

Apr 17, 2023 → Jun 24, 2024

NCT ID

NCT05827978

About mRNA-1010

mRNA-1010 is a phase 3 stage product being developed by Moderna for Seasonal Influenza. The current trial status is completed. This product is registered under clinical trial identifier NCT05827978. Target conditions include Seasonal Influenza.

What happened to similar drugs?

20 of 20 similar drugs in Seasonal Influenza were approved

Approved (20) Terminated (0) Active (0)

✅montelukastMerckApproved

✅Cell-derived influenza vaccine + Egg-derived influenza vaccineNovartisApproved

✅KetotifenNovartisApproved

✅Fexofenadine HClSanofiApproved

✅Placebo nasal spray + Triamcinolone acetonide aqueous (TAA-AQ) nasal spray (NASACORT AQ) + Placebo nasal spray + Claritin® SyrupSanofiApproved

✅fexofenadine HClSanofiApproved

✅levocetirizine dihydrochlorideUCBApproved

Clinical Trials (8)

NCT ID	Phase	Status	Start	Completion	Indication
NCT06602024	Phase 3	Completed	Sep 16, 2024	Aug 21, 2025	Seasonal Influenza
NCT05868382	Phase 2	Completed	May 15, 2023	Dec 19, 2023	Influenza
NCT05827978	Phase 3	Completed	Apr 17, 2023	Jun 24, 2024	Seasonal Influenza
NCT05606965	Phase 2	Completed	Nov 2, 2022	Nov 13, 2025	Influenza
NCT05585632	Phase 1	Completed	Oct 14, 2022	Feb 28, 2024	SARS-CoV-2, Influenza, RSV
NCT05566639	Phase 3	Completed	Sep 14, 2022	Jan 5, 2024	Seasonal Influenza
NCT05415462	Phase 3	Completed	Jun 6, 2022	Sep 4, 2023	Seasonal Influenza
NCT04956575	Phase 2	Completed	Jul 6, 2021	Sep 27, 2022	Seasonal Influenza

Competing Products

20 competing products in Seasonal Influenza

See all competitors

Product	Company	Stage	Hype Score
mRNA-1273	Moderna	Phase 1	0
mRNA-1010	Moderna	Phase 3	0
mRNA-1011.1	Moderna	Phase 2	0
mRNA-1010	Moderna	Phase 3	0
mRNA-1010	Moderna	Phase 3	0
mRNA-1030	Moderna	Phase 2	0
mRNA-1010	Moderna	Phase 2	0
Bilastine + Desloratadine + Placebo	Yuhan	Phase 3	40
ASP4070 + Placebo	Astellas Pharma	Phase 2	35
S-555739 Dose 1 + S-555739 Dose 2 + Cetirizine HCl Dose 1 + S-555739 placebo + Cetirizine HCl placebo	Shionogi	Phase 2	35
Cetirizine + High dose ONO-4053 + Low dose ONO-4053 + Placebo	Ono Pharmaceutical	Phase 2	35
Ciclesonide nasal aerosol 37 mcg + ciclesonide nasal aerosol 74 mcg + Placebo	Sumitomo Pharma	Phase 3	40
80 mcg Ciclesonide + 160 mcg Ciclesonide + Placebo	Sumitomo Pharma	Phase 3	40
Ciclesonide HFA 160 μg + Ciclesonide HFA 80 μg + Placebo	Sumitomo Pharma	Phase 3	40
GSP 301-1 NS (QD) + GSP 301-2 NS (BID) + GSP 301 Placebo NS + Olopatadine HCl-1 NS (QD) + Olopatadine HCl-2 NS (BID) + Mometasone Furoate-1 NS (QD) + Mometasone Furoate-2 NS (BID)	Glenmark Pharmaceuticals	Phase 2	35
Molo 1 (also referred as GSP 301-2 NS) + Molo 2 (also referred as GSP 301-1 NS) + Placebo nasal spray + DYMISTA nasal spray + PATANASE nasal spray	Glenmark Pharmaceuticals	Phase 2	35
JNJ38224342 + JNJ38224342/placebo + JNJ38224342/placebo + JNJ38224342/placebo	Johnson & Johnson	Phase 1	29
Ciclesonide + Placebo	AstraZeneca	Phase 3	40
Ciclesonide + Placebo	AstraZeneca	Phase 3	40
Ciclesonide HFA + Ciclesonide HFA + Ciclesonide HFA + Placebo	AstraZeneca	Phase 2	35